Willingmed, a Beijing-based company specializing in molecular biology for clinical infection precision diagnosis, has reportedly secured hundreds of millions of renminbi in a Series B financing round. The round was led by Galaxy Capital, Haier Capital, and Hunan Hi-Tech Venture Capital Health & Elderly Care Fund. The funds raised will be allocated towards product market filing, new product development, and the construction of a pathogenic microbe laboratory, among other strategic initiatives.
High-Throughput Technologies and Product Launches
Willingmed is recognized for its advanced technologies, including high throughput next-generation sequencing (NGS), microfluidic chips, and transcriptome sequencing. The company has recently launched several innovative diagnostic products, such as DR co-examination for lower respiratory tract infections, double layer detection for hypersensitive peripheral blood flow infection, and the V2.0 version of intelligent report interpretation. These products demonstrate Willingmed’s commitment to enhancing diagnostic accuracy and efficiency in clinical settings.
PathoLab and PathoReport Systems
In 2021, Willingmed completed the development of the PathoLab high throughput pathogen laboratory system and the PathoReport automated intelligent reporting system, both of which are firsts in China. These systems represent a significant advancement in the field of clinical infection diagnostics, streamlining the process from sample analysis to report generation and providing a robust foundation for the company’s growth in the molecular biology diagnostics market.-Fineline Info & Tech
